GlassScriptPhysician profile
Joseph Sahab
NPI 1346233772
$405.89
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $12.87 · 2021: $69.80 · 2022: $14.54.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $169.00 | 2019 | |
| W. L. Gore & Associates, INC. | $83.53 | 2019 | |
| Boston Scientific Corporation | $70.47 | 2019-2021 | |
| Esperion Therapeutics, INC. | $15.62 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.54 | 2022 | |
| Welch Allyn | $14.08 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.42 | 2019 | |
| Amarin Pharma, INC. | $12.87 | 2020 | |
| Teleflex LLC | $12.36 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Sahab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.